Non-Small Cell Lung Cancer
LUAD and LUSC can overlap clinically while differing biologically, which motivates distinct diagnostic and therapeutic strategies. The study did not report independent external validation for its LUAD-LUSC findings. No standard treatment e…
2 sources - 9 claims
LUAD and LUSC can overlap clinically while differing biologically, which motivates distinct diagnostic and therapeutic strategies. The study did not report independent external validation for its LUAD-LUSC findings. No standard treatment exists for NSCLC with leptomeningeal metastases. Systemic chemotherapy is limited for leptomeningeal metastases because the blood-brain barrier restricts central nervous system drug penetration. The study used TCGA-derived LUAD and LUSC cohorts as its data foundation. The study focuses on classifying LUAD and LUSC subtypes and discovering biomarkers for non-small cell lung cancer. Traditional treatment options for NSCLC with leptomeningeal metastases include radiotherapy, targeted therapy, systemic chemotherapy, intrathecal chemotherapy, and immunotherapy.